Novo Nordisk Partners with Flagship Pioneering for Development of Novel Obesity Treatments
Denmark-based pharmaceutical giant Novo Nordisk (CPH: NOVO-B) has announced a partnership with life sciences venture...
Novo Nordisk
Novo Nordisk’s Q1 2024 Global Sales Surge 24% YOY on Strength of GLP-1 Therapies
Denmark-based pharmaceutical giant Novo Nordisk (CPH: NOVO-B) reported a substantial 24% year-on-year (YOY) increase in...
U.S. Judge Dismisses Johnson & Johnson and Bristol-Myers Squibb Lawsuits Against Drug-Pricing Provisions in Inflation Reduction Act
In a recent legal development, a U.S. federal court judge has rejected the legal challenges...
China’s Insulin Volume-Based Procurement Tender Results Renewed with 17% Higher Contracted Value
The renewal of winning bids from the insulin volume-based procurement (VBP) tender, initially held in...
Jiuyuan Gene’s Semaglutide Biosimilar Market Filing Accepted for Review in China
Hangzhou Jiuyuan Gene Engineering Co., Ltd., based in China, has announced that its market approval...
Novo Nordisk Acquires Cardior for €1.025 Billion to Strengthen Cardiovascular Portfolio
Denmark-based Novo Nordisk (CPH: NOVO-B) has announced a significant agreement to acquire Germany’s Cardior, a...
Novo Nordisk Expands Benzalkonium Chloride Distribution with Actylis Across Europe
Denmark’s Novo Nordisk (CPH: NOVO-B), through its Pharmatech division, announced a partnership this week with...
Novo Nordisk Invests RMB 4 Billion to Expand Sterile Manufacturing in Tianjin
Novo Nordisk (NYSE: NVO), a Denmark-based leader in diabetes care, has announced a substantial investment...
Novo Nordisk’s Wegovy Leads in Total US Prescriptions for Weight-Loss Market
Novo Nordisk (CPH: NOVO-B), a leading pharmaceutical company, has seen its weight-loss drug Wegovy (semaglutide)...
CNIPA Invalidates Novo Nordisk’s Victoza Patent, Opening Door for Chinese Biosimilars
The China National Intellectual Property Administration (CNIPA) has declared invalid the patent No. 201510572124.1 held...
FDA Approves Wegovy for Cardiovascular Risk Reduction in Obese Patients, First of Its Kind
The U.S. Food and Drug Administration (FDA) granted an indication extension approval last week to...
Novo Nordisk’s Anti-Obesity Drug Wegovy Eyed for China Launch in 2024
Novo Nordisk (NYSE: NVO), a leading diabetes company based in Denmark, has reportedly informed investors...
Novo Nordisk’s Ozempic Meets Phase III Endpoints in Type 2 Diabetes and Chronic Kidney Disease Study
Novo Nordisk (NYSE: NVO), a Denmark-based pharmaceutical company, has this week published results from a...
Novo Nordisk Partners with Neomorph to Target Undruggable Diseases with Molecular Glue Degraders
Danish pharmaceutical giant Novo Nordisk (CPH: NOVO-B) has entered into a partnership with US-based Neomorph...
Novo Holdings to Acquire Catalent for $16.5 Billion in Strategic Move to Enhance Biopharmaceutical Capacity
Novo Holdings, the principal shareholder of Denmark’s Novo Nordisk (CPH: NOVO-B), has announced a definitive...
Novo Nordisk Delivers Strong 2023 Results with Record-Breaking Sales
Novo Nordisk A/S (NYSE: NVO), a Denmark-based pharmaceutical company, has announced its financial results for...
Gan & Lee Pharmaceuticals Receives Bolivian Approval for Insulin Aspart, Expanding Access to Rapid-Acting Insulin
Gan & Lee Pharmaceuticals (SHA: 603087), a Chinese pharmaceutical company, has announced that it has...
Novo Nordisk’s Rybelsus Approved for Type 2 Diabetes in China, Setting New Oral Treatment Standard
Novo Nordisk (NYSE: NVO), a major Danish pharmaceutical company, has received approval from China’s National...
Novo Nordisk’s IcoSema Shows Promise in Late-Stage Trial for Type 2 Diabetes Management
Danish pharmaceutical giant Novo Nordisk (CPH: NOVO-B) has announced positive results from a late-stage trial...
Sanofi CEO Paul Hudson Rules Out GLP-1 Competition, Eyes Next-Gen Weight-Management Therapies
Paul Hudson, CEO of Sanofi (NASDAQ: SNY), stated this week that the France-based pharmaceutical company...